Welcome to our dedicated page for CEL-SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CEL-SCI Corporation filings document a clinical-stage biotechnology issuer funding the development of Multikine through registered securities offerings and reporting material corporate actions. Registration statements and prospectus-related filings describe common stock issuance capacity, use of proceeds for Multikine development, working capital, risk factors, operating and financial results, and the company's capital structure.
Current reports on Form 8-K record placement agency agreements, closed equity offerings, and amendments to the company's Shareholder Rights Agreement, including modifications to security-holder rights. The filing record also provides formal disclosure around governance, material agreements, and financing terms tied to CEL-SCI's cancer immunotherapy development business.
CEL SCI CORP director and CEO Geert Kersten reported a significant insider purchase through a related trust. On May 14, 2026, the de Clara Trust, for which Mr. Kersten serves as trustee, bought 300,000 shares of restricted common stock directly from the company at $1.20 per share, equal to the most recent closing price on May 13, 2026.
After this transaction, Mr. Kersten is shown with 210,950 common shares held directly and 311,547 common shares held indirectly as trustee of the de Clara Trust. The filing shows no derivative securities remaining after this activity.
CEL-SCI Corporation reported another loss-making quarter as it advances its lead cancer immunotherapy, Multikine, toward a planned Phase 3 confirmatory registration study. For the six months ended March 31, 2026, the company posted a net loss of about $10.9 million, improving from $13.6 million a year earlier as both research and development and general and administrative expenses declined.
Cash and cash equivalents fell sharply to $1.9 million from $11.0 million at September 30, 2025, while total assets dropped to $17.7 million. Management discloses “substantial doubt” about CEL-SCI’s ability to continue as a going concern and estimates the planned confirmatory Multikine study will cost roughly $30–$35 million, requiring additional financing.
The company highlights Phase 3 data in a defined head and neck cancer target population, where it reports a 5‑year survival rate of 73% with Multikine versus 45% without, and a hazard ratio of 0.35, and is preparing global regulatory filings while relying heavily on future equity or partnership funding to sustain operations.
CEL-SCI Corporation has signed a strategic partnership with Amarox to register, commercialize, and distribute its investigational cancer immunotherapy Multikine for head and neck cancer in Saudi Arabia, with an option to expand into Gulf Cooperation Council countries.
Amarox will lead all Saudi Food and Drug Authority regulatory activities, including seeking Breakthrough Medicine Designation, and will become the exclusive distributor in Saudi Arabia if SFDA approval is granted. Net revenue from Multikine sales in Saudi Arabia will be shared equally on a 50%/50% basis, while CEL-SCI keeps global intellectual property and manufacturing rights. The deal targets a fast-growing Saudi cancer immunotherapy market projected to reach $2.7 billion by 2033 and aligns with Saudi Arabia’s Vision 2030 health initiatives.
CEL SCI CORP director and Chief Executive Officer Geert R. Kersten reported buying additional company shares. On May 13, 2026, he purchased 100,000 shares of restricted common stock directly from the company at $1.19 per share, equal to the May 12, 2026 closing price. Following this transaction, his direct holdings increased to 222,497 common shares, indicating a substantial expansion of his personal equity stake.
CEL-SCI Corporation priced a best-efforts public offering of 6,000,000 shares of common stock at $1.20 per share, for expected gross proceeds of about $7.2 million before fees and expenses. The offering is expected to close on May 13, 2026, subject to customary closing conditions.
The company plans to use the cash to continue developing its investigational cancer immunotherapy Multikine, as well as for general corporate purposes and working capital. Multikine has been dosed in over 740 patients and has received FDA Orphan Drug designation for neoadjuvant treatment of head and neck cancer, but it is not yet approved for sale.
CEL-SCI Corporation is offering 6,000,000 shares of its common stock at $1.20 per share on a best-efforts basis. The company expects net proceeds of approximately $6.5M to fund continued development of Multikine and for general corporate purposes. There is no minimum offering amount, the placement agent will use reasonable best efforts to arrange sales, and delivery is expected on or about May 13, 2026.
The prospectus states 8,493,111 shares were outstanding as of May 11, 2026, and assumes no exercise of 710,491 options or 36,421 warrants noted in the filing. The offering is structured so proceeds will be available for immediate use by the company upon receipt.
CEL-SCI Corporation is registering up to 4,885,993 shares of common stock, Pre-Funded Warrants to purchase up to 4,885,993 shares, and 4,885,993 underlying shares in a primary, best efforts offering. The assumed price is $3.07 per share, with estimated net proceeds of about $13.7 million.
The company plans to use the funds mainly to advance its lead cancer immunotherapy Multikine, including a planned 212‑patient confirmatory Phase III study, and for general corporate purposes. Common shares outstanding would rise from 8,492,777 to 13,378,770 if all shares are sold and no Pre‑Funded Warrants are issued, meaning substantial dilution to new investors.
CEL‑SCI is a late clinical‑stage biotech focused on immunotherapies for head and neck cancer and rheumatoid arthritis. Recent financials show significant operating and net losses, going‑concern uncertainty, and material weaknesses in internal controls, underscoring its dependence on raising capital and obtaining regulatory approval for Multikine.